Stevens First Principles Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500	Closed	-$68K	–	193
2015 Q2	$68K	Buy	500 +400	+400%	+$49.6K	0.04%	122
2015 Q1	$12K	Sell	100 -200	-67%	-$21.2K	0.01%	179
2014 Q4	$27K	Hold	300	–	–	0.02%	148
2014 Q3	$22K	Hold	300	–	–	0.01%	176
2014 Q2	$19K	Buy	300 +50	+20%	+$3.02K	0.01%	173
2014 Q1	$17K	Sell	250 -150	-38%	-$11.1K	0.01%	163
2013 Q4	$28K	Hold	400	–	–	0.02%	155
2013 Q3	$29K	Hold	400	–	–	0.02%	151
2013 Q2	$22K	Buy	+400	New	+$24.9K	0.02%	159

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stevens First Principles Investment Advisors's BMRN Position: Q3 2015 in Review

Stevens First Principles Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 500 shares — an estimated $68K sold.

Stevens First Principles Investment Advisors first reported a position in BMRN in Q2 2013 and held it in 9 quarters. The position peaked at $68K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

Stevens First Principles Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 500 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $68K.
Stevens First Principles Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Stevens First Principles Investment Advisors's BioMarin Pharmaceuticals position peaked at $68K in Q2 2015.
393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.